PLCγ1 inhibition-driven autophagy of IL-1β-treated chondrocyte confers cartilage protection against osteoarthritis,involving AMPK,Erk and Akt

Previous studies identified the involvement of phosphoinositide-specific phospholipase C (PLC) γ1 in some events of chondrocytes. This study aims to investigate whether and how PLCγ1 modulates autophagy to execute its role in osteoarthritis (OA) progression. Rat normal or human OA chondrocytes were pretreated with IL-1β for mimicking or sustaining OA pathological condition. Using Western blotting, immunoprecipitation, qPCR, immunofluorescence and Dimethylmethylene blue assays, and ELISA and transmission electron microscope techniques, we found that PLCγ1 inhibitor U73122 enhanced Collagen II, Aggrecan and GAG levels, accompanied with increased LC3B-II/I ratio and decreased P62 expression level, whereas autophagy inhibitor Chloroquine partially diminished its effect. Meanwhile, U73122 dissociated Beclin1 from Beclin1-IP3R-Bcl-2 complex and blocked mTOR/ULK1 axis, in which the crosstalk between PLCγ1, AMPK, Erk and Akt were involved. Additionally, by haematoxylin and eosin, Safranin O/Fast green, and immunohistochemistry staining, we observed that intra-articular injection of Ad-shPLCγ1-1/2 significantly enhanced Collagen and Aggrecan levels, accompanied with increased LC3B and decreased P62 levels in a rat OA model induced by anterior cruciate ligament transection and medial meniscus resection. Consequently, PLCγ1 inhibition-driven autophagy conferred cartilage protection against OA through promoting ECM synthesis in OA chondrocytes in vivo and in vitro, involving the crosstalk between PLCγ1, AMPK, Erk and Akt.     

受体相互作用蛋白质激酶3通过上调整合素β3促进骨关节炎相关病变

骨关节炎（osteoarthritis,OA）是最常见的慢性致残性关节疾患,目前尚无针对病因的有效治疗手段。程序性坏死在多种疾病中扮演关键角色,受体相互作用蛋白质激酶3（receptor-interacting protein kinase 3, RIP3）是程序性坏死进程的关键调控因子。有研究显示,RIP3在人与鼠骨关节炎退变软骨组织中表达水平显著上调,提示程序性坏死的发生,但RIP3在软骨中的具体病生理角色仍不明确。本研究拟对过表达RIP3前后的软骨细胞转录物组进行测序分析,探索RIP3在骨关节炎进程中发挥作用的具体机制。RNA测序结果显示,RIP3的过表达诱发软骨细胞中244个基因表达上调,277个表达下调。通过进一步构建基因间共表达作用网络,筛选出16个候选靶基因在mRNA水平进行验证,证实RIP3对磷脂酰肌醇3激酶调节亚单位5（phosphoinositide-3-kinase, regulatory subunit 5,Pik3r5）、整合素β3（integrin subunit beta 3,Itgb3）及成髓细胞瘤转录因子第2亚型（MYB proto-oncogene like 2,Mybl2）的表达上调作用最为显著。CCK-8以及乳酸脱氢酶活性检测结果表明,利用siRNA沉默Itgb3的表达可显著抑制RIP3诱发的软骨细胞活力下降及程序性坏死,同时也抑制了RIP3对软骨细胞中分解代谢相关基因Mmp1、Mmp13与Il6的表达上调作用,以及其对合成代谢相关基因Acan、Col2a1与Sox9的下调作用。本研究证实,RIP3通过上调软骨细胞中Itgb3的表达诱发软骨细胞坏死与软骨基质代谢紊乱,并最终导致软骨退变,为骨关节炎的临床治疗提供了新靶点,同时进一步明确了程序性坏死的病理生理学意义。     

Lysoglycerophospholipids in chronic inflammatory disorders: The PLA2/LPC and ATX/LPA axes

Lysophosphatidylcholine (LPC) and lysophosphatidic acid (LPA), the most prominent lysoglycerophospholipids, are emerging as a novel class of inflammatory lipids, joining thromboxanes, leukotrienes and prostaglandins with which they share metabolic pathways and regulatory mechanisms. Enzymes that participate in LPC and LPA metabolism, such as the phospholipase A₂ superfamily (PLA₂) and autotaxin (ATX, ENPP2), play central roles in regulating LPC and LPA levels and consequently their actions. LPC/LPA biosynthetic pathways will be briefly presented and LPC/LPA signaling properties and their possible functions in the regulation of the immune system and chronic inflammation will be reviewed. Furthermore, implications of exacerbated LPC and/or LPA signaling in the context of chronic inflammatory diseases, namely rheumatoid arthritis, multiple sclerosis, pulmonary fibrosis and hepatitis, will be discussed. This article is part of a Special Issue entitled Advances in Lysophospholipid Research.     

High glucose induces vascular endothelial growth factor production in human synovial fibroblasts through reactive oxygen species generation

Background

Diabetes is an independent risk factor of osteoarthritis (OA). Angiogenesis is essential for the progression of OA. Here, we investigated the intracellular signaling pathways involved in high glucose (HG)-induced vascular endothelial growth factor (VEGF) expression in human synovial fibroblast cells.

Methods

HG-mediated VEGF expression was assessed with qPCR and ELISA. The mechanisms of action of HG in different signaling pathways were studied using Western blotting. Knockdown of proteins was achieved by transfection with siRNA. Chromatin immunoprecipitation assays were used to study in vivo binding of c-Jun to the VEGF promoter.

Results

Stimulation of OA synovial fibroblasts (OASF) with HG induced concentration- and time-dependent increases in VEGF expression. Treatment of OASF with HG increased reactive oxygen species (ROS) generation. Pretreatment with NADPH oxidase inhibitor (APO or DPI), ROS scavenger (NAC), PI3K inhibitor (Ly294002 or wortmannin), Akt inhibitor, or AP-1 inhibitor (curcumin or tanshinone IIA) blocked the HG-induced VEGF production. HG also increased PI3K and Akt activation. Treatment of OASF with HG increased the accumulation of phosphorylated c-Jun in the nucleus, AP-1-luciferase activity, and c-Jun binding to the AP-1 element on the VEGF promoter.

Conclusions

Our results suggest that the HG increases VEGF expression in human synovial fibroblasts via the ROS, PI3K, Akt, c-Jun and AP-1 signaling pathway.

General significance

We link high glucose on VEGF expression in osteoarthritis.     

木霉对草酸耐受和消除作用的初步分析

【目的】草酸(Oxalic acid,OA)是灰霉菌(Botrytis cinerea)等植物致病菌的致病因子,一些木霉(Trichoderma spp.)生防菌可消除草酸并降低植物发病率,但其消除草酸防治病害的途径和机制尚未研究透彻。【方法】首先从42株木霉菌株中筛选出一株在30 mmol/L草酸胁迫下耐受性最强的哈茨木霉T.harzianum LTR-2,通过形态学方法观察和原位分析了不同浓度草酸胁迫下LTR-2的发育特征变化,并测定了草酸消除水平、滤液p H和菌丝干重,分析了LTR-2在草酸为唯一碳源的生长情况。通过Real-time PCR分析了OXDC基因LTR_4445在草酸处理下的表达水平。【结果】在PDA固体培养基中,25°C半光照条件下培养5 d,在草酸浓度为50-80 mmol/L时,LTR-2可存活,但无正常菌落形态;在30-50 mmol/L浓度下,LTR-2先萌发厚垣孢子,而后再次萌发菌丝形成菌落;在30 mmol/L浓度下,LTR-2发育正常,仅生长速度减缓。25°C、160 r/min振荡培养5 d,LTR-2可消除草酸。在20 mmol/L浓度时,草酸消除率最高,为66.50%;10 mmol/L浓度中的消除率次之,为55.06%。草酸浓度50 mmol/L时,消除能力下降为6.75%-38.94%。相应地,培养液p H被不同程度地提高,在10、20 mmol/L草酸浓度下提高的幅度更大。当草酸浓度20 mmol/L时,木霉的菌丝干重有不同程度的提高。将草酸作为唯一碳源进行液体培养5 d时,在10、20 mmol/L浓度下,LTR-2可形成肉眼可见的绿色菌丝球,但高于50 mmol/L条件下无法生长。草酸处理下,LTR_4445表达水平上调。【结论】通过分析LTR-2在草酸胁迫条件下的形态特征变化及消除草酸的特性,暗示在木霉消除草酸作用中除了已知的草酸降解代谢途径,还存在响应草酸胁迫模式的转变、将草酸作为前体转化为营养物质的途径等其他消除途径。     

Cyanobacterial bioactive metabolites—A review of their chemistry and biology

Cyanobacterial blooms occur when algal densities exceed baseline population concentrations. Cyanobacteria can produce a large number of secondary metabolites. Odorous metabolites affect the smell and flavor of aquatic animals, whereas bioactive metabolites cause a range of lethal and sub-lethal effects in plants, invertebrates, and vertebrates, including humans. Herein, the bioactivity, chemistry, origin, and biosynthesis of these cyanobacterial secondary metabolites were reviewed. With recent revision of cyanobacterial taxonomy by Anagnostidis and Komárek as part of the Süβwasserflora von Mitteleuropa volumes 19(1–3), names of many cyanobacteria that produce bioactive compounds have changed, thereby confusing readers. The original and new nomenclature are included in this review to clarify the origins of cyanobacterial bioactive compounds.Due to structural similarity, the 157 known bioactive classes produced by cyanobacteria have been condensed to 55 classes. This review will provide a basis for more formal procedures to adopt a logical naming system. This review is needed for efficient management of water resources to understand, identify, and manage cyanobacterial harmful algal bloom impacts.     

Effects of tau phosphorylation on proteasome activity

Dysfunction of proteasome contributes to the accumulation of the abnormally hyperphosphorylated tau in Alzheimer's disease. However, whether tau hyperphosphorylation and accumulation affect the activity of proteasome is elusive. Here we found that a moderate tau phosphorylation activated the trypsin-like activity of proteasome, whereas further phosphorylation of tau inhibited the activity of the protease in HEK293 cells stably expressing tau441. Furthermore, tau hyperphosphorylation could partially reverse lactacystin-induced inhibition of proteasome. These results suggest that phosphorylation of tau plays a dual role in modulating the activity of proteasome.     

Cdkn2a示踪小鼠:研究创伤性骨关节炎软骨退变细胞衰老的新模型

骨关节炎(osteoarthritis,OA)是临床上最为常见的老年性运动系统疾病之一。研究表明,衰老是OA发生发展的重要影响因素之一,但其具体作用及机制尚未完全清楚。本研究通过CRISPR/Cas9技术,建立了Cdkn2a-e(Luc-2A-tdTomato-2A-CreERT2-WPRE-pA)1定点敲入的杂合子小鼠模型,可在小鼠活体内追踪衰老经典标记物Cdkn2a(p16, p16INK4a)的表达情况,结合前交叉韧带横断术(ACLT)诱导OA小鼠模型,将OA病理进程中的衰老变化在体外直观呈现,明确衰老与OA之间的关系。本研究选取10 ～ 12周龄Cdkn2a小鼠,随机分为非手术对照组、假手术组和ACLT组,通过ACLT手术在小鼠中构建OA的模型,术后4周收取动物进行活体荧光成像检测显示,ACLT组术后4周的小鼠膝关节局部Cdkn2a荧光表达升高(P＜0.05),小鼠膝关节组织切片的番红O固绿染色显示,4周时ACLT组膝关节软骨出现退变(P＜0.05),对小鼠膝关节组织进行Cdkn2a免疫组织化学染色,相较其他2个组,ACLT组的小鼠膝关节组织软骨表面Cdkn2a染色更深。研究结果显示,通过手术诱导的OA模型在局部具有衰老的表现,这进一步验证了衰老和OA的关系。同时,该Cdkn2a示踪小鼠模型能够在活体小鼠内体现衰老的进展。结合影像学检查,可以实时观察衰老和OA发生、进展的关系,为衰老与OA疾病机制的研究提供了良好的模型,也为今后进行靶向衰老进行OA的治疗提供了很好的研究工具。     

小分子药物BNTA通过上调Insig1缓解高胆固醇引起的骨关节炎

骨关节炎(osteoarthritis,OA)是运动系统常见的退行性疾病,具有高发病率和高致残率。骨关节炎的发病机制目前尚不明确,既往研究认为骨关节炎发病主要与创伤因素相关,而近期研究表明,以胆固醇代谢异常为主的代谢性因素同样与骨关节炎密切相关,骨关节炎的治疗以早期对症治疗和晚期手术治疗为主,尚无针对病因的特效药物。既往研究中发现,有一种具有软骨保护作用的小分子药物BNTA,其在创伤引起的骨关节炎中具有较好的疗效,但其对高胆固醇引起的骨关节炎的作用尚不明确。本研究为探究BNTA对高胆固醇引起的骨关节炎的治疗作用及其机制,采用高胆固醇饮食构建了大鼠骨关节炎模型,取膝关节石蜡切片进行组织学评估,使用油红O染色评估大鼠软骨细胞内的脂质积聚情况,使用RT-qPCR、免疫荧光和免疫组化评估软骨细胞合成代谢、分解代谢及胆固醇代谢相关基因和蛋白质的表达。结果显示,BNTA可缓解高胆固醇大鼠骨关节炎模型中的病理表现,改善OARSI评分。在大鼠软骨细胞中,BNTA可促进合成代谢相关基因col2、sox9、acan的表达,抑制分解代谢相关基因mmp13、adamts5的表达,可改善高胆固醇引起的大鼠软骨细胞脂质积聚。在大鼠软骨细胞和高胆固醇大鼠骨关节炎模型中BNTA均可上调Insig1表达。本研究证实,高胆固醇可在体内和体外实验中加重骨关节炎,可引起大鼠软骨细胞脂质积聚增加。在体内和体外实验中BNTA均能缓解高胆固醇引起的骨关节炎表型,改善软骨细胞内的异常脂质积聚,其作用可能为通过上调Insig1抑制细胞内的胆固醇生物合成,从而缓解脂质异常积聚。